drugset / Trial / NCT00719693

Assessment of the Effect of Food on ABT-143 Bioavailability

NCT00719693

Phase 1 Completed 115 enrolled AstraZeneca
RandomizedCrossoverOpen-labelBasic science

Summary

Single-dose, open-label, two-period crossover study of ABT-143

Timeline

Start
2008-07
Primary completion
2008-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule
Subject fenofibric acid Small molecule

Indications

No indication recorded.